Clinical Report: Discovery and validation of mismatch repair-associated biomarkers for prognostic prediction in glioma

Overview

This study develops a prognostic model based on mismatch repair (MMR)-associated genes in glioma patients, identifying MCM8 as a significant biomarker influencing temozolomide (TMZ) sensitivity.

Background

Gliomas are highly malignant brain tumors with poor prognoses, often characterized by MMR deficiency. Understanding the molecular mechanisms and identifying reliable biomarkers are crucial for glioma management.

Data Highlights

Key Findings

• A prognostic model based on eight MMR-related genes was developed.
• Patients classified as high-risk showed significantly lower overall survival rates.
• The model was validated using the CGGA dataset.
• Distinct immune infiltration and tumor microenvironment differences were observed across risk categories.
• MCM8 overexpression increased glioma cell sensitivity to temozolomide (TMZ).
• MCM8 depletion reduced sensitivity to TMZ, indicating its potential as a therapeutic target.

Clinical Implications

Further investigation is warranted to explore the potential of MCM8 in glioma treatment.

Conclusion

This research highlights MCM8 as a targetable biomarker in glioma.

Related Resources & Content

1. Acta Neuropathologica, 2023 -- Immune Checkpoint Blockade May Offer Benefits for a Unique Subtype of Adult Glioblastoma Characterized by De Novo Replication Repair Deficiency and IDH-Wildtype Status
2. Acta Neuropathologica, 2018 -- DNA Methylation Patterns of DNA Damage Response Genes and Treatment Outcomes with Radiotherapy or Temozolomide in IDH Mutant Low-Grade Gliomas from EORTC 22033 Study
3. Acta Neuropathologica, 2020 -- IDH-Mutant Astrocytoma with Primary Mismatch Repair Deficiency: A Unique Variant Associated with Adverse Outcomes
4. The ASCO Post, 2025 -- Extent and Impact of Primary MMRD in Gliomas Among Children and AYAs
5. What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas - PMC, 2024
6. Agnostic Cancer Therapies (PDQ®) - NCI
7. Investigation of mismatch repair protein expression in glioma - ScienceDirect
8. What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas - PMC
9. Agnostic Cancer Therapies (PDQ®) - NCI
10. Investigation of mismatch repair protein expression in glioma - ScienceDirect